

Andrew K Mcpherson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1715247/publications.pdf>

Version: 2024-02-01

14
papers

663
citations

933447

10
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

863
citing authors

#	ARTICLE	IF	CITATIONS
1	Click chemistry in materials synthesis. 1. Adhesive polymers from copper-catalyzed azide-alkyne cycloaddition. <i>Journal of Polymer Science Part A</i> , 2004, 42, 4392-4403.	2.3	394
2	Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1546-1559.	6.4	46
3	Inhibitors of ABL and the ABL-T315I Mutation. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 905-921.	2.1	42
4	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine as a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 602-608.	2.2	41
5	Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5546-5550.	2.2	26
6	The design and preliminary structure-activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5812-5818.	2.2	23
7	Synthesis of 5'-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies. <i>Molecules</i> , 2017, 22, 1356.	3.8	23
8	Formation of the N2-acetyl-2,6-diaminopurine oligonucleotide impurity caused by acetyl capping. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3243-3246.	2.2	21
9	Metabolism and Pharmacokinetics of a Novel Src Kinase Inhibitor TG100435 ([7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and Its Active N-Oxide Metabolite TG100855 ([7-(2,6-Dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-[4-[2-(1-oxo-pyrrolidin-1-yl)-ethoxy]-phenyl]-amine). <i>Drug Metabolism and Disposition</i> , 2007, 35, 929-936.	3.3	14
10	Conversion of adenine to 5-amino-4-pyrimidinylimidazole caused by acetyl capping during solid phase oligonucleotide synthesis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3468-3471.	2.2	12
11	Perspectives on the Designation of Oligonucleotide Starting Materials. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 93-113.	3.6	10
12	Development of novel benzotriazines for drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 33-49.	5.0	9
13	An Improved Process for the Manufacture of 5'-O-(4,4'-Dimethoxytrityl)-N ² -isobutyryl-2'-O-(2-methoxyethyl)guanosine. <i>Organic Process Research and Development</i> , 2020, 24, 2583-2590.		2
14	Impurity Qualification Toxicology Study for a 2'-O-Methoxyethyl-Modified Antisense Inhibitor in Mice. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 14-21.	3.6	0